Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma

Cells. 2023 Mar 28;12(7):1030. doi: 10.3390/cells12071030.

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells in the bone marrow and is characterized by the clonal proliferation of B-cells producing defective monoclonal immunoglobulins. Despite the latest developments in treatment, drug resistance remains one of the major challenges in the therapy of MM. The crosstalk between MM cells and other components within the bone marrow microenvironment (BME) is the major determinant of disease phenotypes. Exosomes have emerged as the critical drivers of this crosstalk by allowing the delivery of informational cargo comprising multiple components from miniature peptides to nucleic acids. Such material transfers have now been shown to perpetuate drug-resistance development and disease progression in MM. MicroRNAs(miRNAs) specifically play a crucial role in this communication considering their small size that allows them to be readily packed within the exosomes and widespread potency that impacts the developmental trajectory of the disease inside the tumor microenvironment (TME). In this review, we aim to provide an overview of the current understanding of the role of exosomal miRNAs in the epigenetic modifications inside the TME and its pathogenic influence on the developmental phenotypes and prognosis of MM.

Keywords: drug resistance; exosomal miRNA; exosome; multiple myeloma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / pathology
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Plasma Cells
  • Tumor Microenvironment

Substances

  • MicroRNAs

Grants and funding

The study was supported in part by the Leukemia and Lymphoma Society of Canada (LLSC) and the Cancer Research Society (CRS).